Table 1 Demography and baseline characteristics
From: An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
Phase 2 | GEMCOVAC-OM (N = 70) | GEMCOVAC-19 (N = 70) |
|---|---|---|
Age, median years (range) | 32 (20–49) | 30 (20–45) |
Gender | ||
Female | 9 (12.9%) | 6 (8.6%) |
Male | 61 (87.1%) | 64 (91.4%) |
Weight, mean in kg (s.d.) | 64.8 (5.07) | 63.7 (5.17) |
Body mass index in kg m−2, mean (s.d.) | 23.2 (1.67) | 23.0 (1.54) |
Phase 3 | GEMCOVAC-OM (N = 2,990) | ChAdOx1 nCoV-19 (N = 133) |
|---|---|---|
Age, median years (range) | 32 (18–81) | 32 (19–57) |
Gender | ||
Female | 951 (31.8%) | 27 (20.3%) |
Male | 2,039 (68.2%) | 106 (79.7%) |
Weight, mean in kg (s.d.) | 62.6 (10.10) | 63.9 (10.63) |
Body mass index in kg m−2, mean (s.d.) | 23.6 (3.43) | 23.8 (3.52) |
